Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentavalent Meningococcal ABCYW vaccine in children, toddlers, and infants
NCT06647407Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, single-blind trial of Meningococcal ABCYW vaccine in meningococcal disease (9 arms), sponsored by Sanofi. Primary endpoints: Unsolicited immediate adverse events at 30 minutes, Solicited injection site reactions or systemic reactions at 7 days and 12 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
Meningococcal ABCYW vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT06647407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647407.